Corcept Therapeutics (CORT) Reaches $19.13 Formed H&S; Shorts at Dht Holdings (DHT) Lowered By 3.71%

Corcept Therapeutics Incorporated (NASDAQ:CORT) Logo

Corcept Therapeutics Incorporated (CORT) formed H&S with $17.98 target or 6.00% below today’s $19.13 share price. Corcept Therapeutics Incorporated (CORT) has $2.20 billion valuation. The stock increased 1.49% or $0.28 during the last trading session, reaching $19.13. About 949,379 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 60.38% since June 14, 2017 and is uptrending. It has outperformed by 47.81% the S&P500. Some Historical CORT News: ; 15/03/2018 – CORCEPT SUIT ALLEGES INFRINGEMENT OF KORLYM PATENTS; 08/05/2018 – CORCEPT THERAPEUTICS INC CORT.O SEES FY 2018 REVENUE $275 MLN TO $300 MLN; 21/05/2018 – Corcept at Non-Deal Roadshow Hosted By Seaport Today; 08/05/2018 – CORCEPT THERAPEUTICS INC CORT.O FY2018 REV VIEW $290.2 MLN — THOMSON REUTERS l/B/E/S; 14/05/2018 – Corcept Closes Above 50-Day Moving Average: Technicals; 08/05/2018 – CORCEPT THERAPEUTICS INC – REAFFIRMED 2018 REVENUE GUIDANCE OF $275 – 300 MLN; 09/05/2018 – Corcept Short-Interest Ratio Rises 28% to 21 Days; 15/03/2018 – CORCEPT THERAPEUTICS FILES SUIT VS TEVA PHARMACEUTICALS; 14/03/2018 Corcept Rises for 7 Days; Tied for Longest Rally; 15/03/2018 – Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents

Dht Holdings Inc (NYSE:DHT) had a decrease of 3.71% in short interest. DHT’s SI was 4.92M shares in June as released by FINRA. Its down 3.71% from 5.11M shares previously. With 819,800 avg volume, 6 days are for Dht Holdings Inc (NYSE:DHT)’s short sellers to cover DHT’s short positions. The SI to Dht Holdings Inc’s float is 4.91%. The stock increased 0.48% or $0.02 during the last trading session, reaching $4.17. About 489,517 shares traded. DHT Holdings, Inc. (NYSE:DHT) has declined 8.67% since June 14, 2017 and is downtrending. It has underperformed by 21.24% the S&P500. Some Historical DHT News: ; 07/05/2018 – DHT Holdings 1Q Loss/Shr 6c; 07/05/2018 – DHT Holdings, Inc. First Quarter 2018 Results; 24/04/2018 – DHT HOLDINGS INC – DHT HAS ENTERED INTO AN AGREEMENT WITH ABN AMRO TO INCREASE COMPANY’S REVOLVING CREDIT FACILITY TO $57.0 MLN; 07/05/2018 – DHT HOLDINGS INC – QTRLY ADJUSTED NET REVENUE $46.2 MLN VS $70.7 MLN; 14/05/2018 – LANSDOWNE ADDED AAL, APC, BABA, DHT, LPG IN 1Q: 13F; 27/04/2018 – DHT Holdings Closes Below 50-Day Moving Average: Technicals; 24/04/2018 – DHT HOLDINGS INC – ENTERED INTO A $485 MLN SECURED CREDIT FACILITY AGREEMENT WITH A SIX YEAR TENOR FOR REFINANCING OF 13 OF COMPANY’S VLCCS; 14/05/2018 – BW GROUP LTD REPORTS 34.2 PCT STAKE IN DHT HOLDINGS INC AS OF MAY 10 – SEC FILING; 25/05/2018 – DHT Holdings Closes Above 200-Day Moving Average: Technicals; 16/03/2018 DHT Holdings Closes Above 50-Day Moving Average: Technicals

Investors sentiment decreased to 1.28 in Q1 2018. Its down 0.21, from 1.49 in 2017Q4. It worsened, as 28 investors sold Corcept Therapeutics Incorporated shares while 55 reduced holdings. 46 funds opened positions while 60 raised stakes. 84.82 million shares or 2.95% less from 87.40 million shares in 2017Q4 were reported. Laurion Capital Limited Partnership reported 28,594 shares. Int Gru holds 58,267 shares. Wellington Mngmt Gru Limited Liability Partnership reported 169,050 shares. Schwab Charles Inv Inc holds 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 490,663 shares. Navellier holds 112,090 shares or 0.28% of its portfolio. S&T State Bank Pa owns 1.25% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 426,257 shares. Moreover, Amer Century Companies has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Blair William And Il stated it has 27,000 shares or 0% of all its holdings. Cambridge Trust stated it has 0.04% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Sit Investment Assoc Incorporated owns 95,650 shares or 0.04% of their US portfolio. Moreover, Thrivent Fincl For Lutherans has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT). Arrowstreet Capital Partnership holds 0.03% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 836,280 shares. Consonance Capital Limited Partnership holds 5.19M shares. Fifth Third Bank & Trust owns 33,211 shares or 0% of their US portfolio. Wisconsin-based Dana Invest Advisors has invested 0.09% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Among 7 analysts covering Corcept Therapeutics (NASDAQ:CORT), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Corcept Therapeutics had 13 analyst reports since February 2, 2017 according to SRatingsIntel. FBR Capital initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) on Thursday, March 8 with “Buy” rating. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Piper Jaffray on Thursday, August 24. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Stifel Nicolaus on Friday, November 3. The firm has “Buy” rating given on Tuesday, June 12 by FBR Capital. Piper Jaffray maintained the shares of CORT in report on Friday, September 8 with “Buy” rating. The firm has “Buy” rating by FBR Capital given on Tuesday, March 20. The company was initiated on Thursday, February 2 by Ladenburg Thalmann. On Thursday, May 31 the stock rating was downgraded by Stifel Nicolaus to “Hold”. The stock has “Buy” rating by Piper Jaffray on Wednesday, October 11. On Friday, April 13 the stock rating was initiated by Seaport Global with “Buy”.

Since January 8, 2018, it had 1 buying transaction, and 7 selling transactions for $1.15 million activity. On Friday, April 6 the insider FISHMAN ROBERT S sold $129,784. The insider GALA RENEE D bought $155,102. $480,312 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) was sold by BAKER G LEONARD JR.

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on August, 7. They expect $0.16 earnings per share, up 60.00% or $0.06 from last year’s $0.1 per share. CORT’s profit will be $18.43M for 29.89 P/E if the $0.16 EPS becomes a reality. After $0.14 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 14.29% EPS growth.

Among 11 analysts covering DHT Holdings (NYSE:DHT), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. DHT Holdings had 33 analyst reports since September 1, 2015 according to SRatingsIntel. Jefferies maintained the shares of DHT in report on Tuesday, May 30 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Wednesday, July 27. The firm has “Buy” rating by Maxim Group given on Friday, April 21. The firm earned “Hold” rating on Monday, January 30 by Stifel Nicolaus. Seaport Global maintained the stock with “Buy” rating in Wednesday, February 7 report. The stock has “Buy” rating by Jefferies on Monday, September 11. Stifel Nicolaus maintained the shares of DHT in report on Friday, July 7 with “Hold” rating. The stock of DHT Holdings, Inc. (NYSE:DHT) earned “Buy” rating by Maxim Group on Thursday, August 3. The company was maintained on Monday, May 7 by Maxim Group. The firm has “Hold” rating given on Friday, April 20 by J.P. Morgan.

DHT Holdings, Inc., through its subsidiaries, owns and operates crude oil tankers primarily in Oslo, Norway and Singapore. The company has market cap of $598.70 million. As of March 21, 2017, its fleet consisted of 21 crude oil tankers, including 19 very large crude carriers and 2 Aframax tankers. It currently has negative earnings.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart